{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:04:35Z","timestamp":1791489875865,"version":"4.3.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Graves\u2019 disease (GD) is an auto-immune cause of hyperthyroidism. First-line treatment often consists of a 12\u201318\u00a0month course of antithyroid drugs (ATD). After discontinuation of ATD, GD relapses in approximately 50% of patients. The \u2018Graves recurrent event after therapy+\u2009\u2019 (GREAT+) score may predict individual relapse chances after ATD discontinuation more accurately based on clinical and laboratory parameters at diagnosis. We investigated the need for the GREAT+\u2009score through an online questionnaire among GD patients and physicians treating GD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An anonymous online questionnaire was distributed to patients and physicians between June 2022 and August 2023.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The questionnaire was completed by 532 patients and 44 physicians. Results showed that 94% of patients were interested in knowing their GREAT+\u2009score at the start of treatment. 55% would consider definite treatment (radioiodine\/thyroidectomy) as first-line treatment in case of a high relapse chance. 98% of the physicians indicated the GREAT\u2009+\u2009score would support patient counseling. 84% may change their advice for first-line treatment if a patient has a high relapse chance based on the score.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients and physicians considered the GREAT+\u2009score as a valuable addition to the current available information which could change treatment decisions. Therefore, external validation of the GREAT+\u2009score is justified to implement this score in clinical practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-024-02358-7","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T07:02:50Z","timestamp":1711350170000},"page":"2499-2505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The need for the GREAT+\u2009score to predict relapse in Graves\u2019 disease: a questionnaire among patients and internal medicine specialists"],"prefix":"10.1007","volume":"47","author":[{"given":"H. I.","family":"Jansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Heuveling van Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. H.","family":"Bisschop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Heijboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bruinstroop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4994-2918","authenticated-orcid":false,"given":"A.","family":"Boelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"issue":"1","key":"2358_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","volume":"6","author":"TF Davies","year":"2020","unstructured":"Davies TF, Andersen S, Latif R, Nagayama Y, Barbesino G, Brito M, Eckstein AK, Stagnaro-Green A, Kahaly GJ (2020) Graves\u2019 disease. Nat Rev Dis Prim 6(1):52. https:\/\/doi.org\/10.1038\/s41572-020-0184-y","journal-title":"Nat Rev Dis Prim"},{"key":"2358_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m41","volume":"368","author":"M Vasileiou","year":"2020","unstructured":"Vasileiou M, Gilbert J, Fishburn S, Boelaert K (2020) Thyroid disease assessment and management: summary of NICE guidance. BMJ 368:m41. https:\/\/doi.org\/10.1136\/bmj.m41","journal-title":"BMJ"},{"issue":"10","key":"2358_CR3","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN et al (2016) 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26(10):1343\u20131421. https:\/\/doi.org\/10.1089\/thy.2016.0229","journal-title":"Thyroid"},{"issue":"15","key":"2358_CR4","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1001\/jama.2023.19052","volume":"330","author":"SY Lee","year":"2023","unstructured":"Lee SY, Pearce EN (2023) Hyperthyroidism: a review. JAMA 330(15):1472\u20131483. https:\/\/doi.org\/10.1001\/jama.2023.19052","journal-title":"JAMA"},{"issue":"9","key":"2358_CR5","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1210\/jc.2013-1954","volume":"98","author":"V Sundaresh","year":"2013","unstructured":"Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS (2013) Comparative effectiveness of therapies for graves\u2019 hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 98(9):3671\u20133677. https:\/\/doi.org\/10.1210\/jc.2013-1954","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2358_CR6","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1210\/jc.2015-3644","volume":"101","author":"XG Vos","year":"2016","unstructured":"Vos XG, Endert E, Zwinderman AH, Tijssen JGP, Wiersinga WM (2016) Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with graves\u2019 hyperthyroidism. J Clin Endocrinol Metab 101(4):1381\u20131389. https:\/\/doi.org\/10.1210\/jc.2015-3644","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2358_CR7","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s40618-016-0516-7","volume":"39","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Masiello E, Magri F, Veronesi G, Bianconi E, Zerbini F, Gaiti M, Spreafico E, Gallo D, Premoli P et al (2016) The phenotype of newly diagnosed Graves\u2019 disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J Endocrinol Invest 39(12):1445\u20131451. https:\/\/doi.org\/10.1007\/s40618-016-0516-7","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2358_CR8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s40618-018-0918-9","volume":"41","author":"E Masiello","year":"2018","unstructured":"Masiello E, Veronesi G, Gallo D, Premoli P, Bianconi E, Rosetti S, Cusini C, Sabatino J, Ippolito S, Piantanida E et al (2018) Antithyroid drug treatment for graves\u2019 disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest 41(12):1425\u20131432. https:\/\/doi.org\/10.1007\/s40618-018-0918-9","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"2358_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1055\/a-0974-3991","volume":"51","author":"SS Zuhur","year":"2019","unstructured":"Zuhur SS, Elbuken G, Yildiz I, Kadioglu P, Erol S, Sahin S, Kilinc F, Akbaba G, Topcu B, Altuntas Y (2019) External validation of the GREAT score in Turkish patients with graves\u02bc hyperthyroidism treated with the titration regimen method of antithyroid drugs: a multicenter study. Horm Metab Res 51(10):627\u2013633","journal-title":"Horm Metab Res"},{"issue":"4","key":"2358_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1530\/eje-16-0986","volume":"176","author":"T Struja","year":"2017","unstructured":"Struja T, Kaeslin M, Boesiger F, Jutzi R, Imahorn N, Kutz A, Bernasconi L, Mundwiler E, Mueller B, Christ-Crain M et al (2017) External validation of the GREAT score to predict relapse risk in graves\u2019 disease: results from a multicenter, retrospective study with 741 patients. Eur J Endocrinol 176(4):413\u2013419. https:\/\/doi.org\/10.1530\/eje-16-0986","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2358_CR11","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1089\/thy.2019.0085","volume":"29","author":"G Sj\u00f6lin","year":"2019","unstructured":"Sj\u00f6lin G, Holmberg M, T\u00f6rring O, Bystr\u00f6m K, Khamisi S, de Laval D, Abraham-Nordling M, Calissendorff J, Lantz M, Hallengren B et al (2019) The long-term outcome of treatment for graves\u2019 hyperthyroidism. Thyroid 29(11):1545\u20131557. https:\/\/doi.org\/10.1089\/thy.2019.0085","journal-title":"Thyroid"},{"issue":"11","key":"2358_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1089\/thy.2005.15.1279","volume":"15","author":"M Abraham-Nordling","year":"2005","unstructured":"Abraham-Nordling M, T\u00f6rring O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J, Wallin G (2005) Graves\u2019 disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 15(11):1279\u20131286. https:\/\/doi.org\/10.1089\/thy.2005.15.1279","journal-title":"Thyroid"},{"issue":"6","key":"2358_CR13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/cen.13611","volume":"88","author":"HM Conaglen","year":"2018","unstructured":"Conaglen HM, Tamatea JAU, Conaglen JV, Elston MS (2018) Treatment choice, satisfaction and quality of life in patients with graves\u2019 disease. Clin Endocrinol 88(6):977\u2013984. https:\/\/doi.org\/10.1111\/cen.13611","journal-title":"Clin Endocrinol"},{"issue":"3","key":"2358_CR14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1089\/thy.2018.0315","volume":"29","author":"O T\u00f6rring","year":"2019","unstructured":"T\u00f6rring O, Watt T, Sj\u00f6lin G, Bystr\u00f6m K, Abraham-Nordling M, Calissendorff J, Cramon PK, Filipsson Nystr\u00f6m H, Hallengren B, Holmberg M et al (2019) Impaired quality of life after radioiodine therapy compared to antithyroid drugs or surgical treatment for graves\u2019 hyperthyroidism: a long-term follow-up with the thyroid-related patient-reported outcome questionnaire and 36-item short form health status survey. Thyroid 29(3):322\u2013331. https:\/\/doi.org\/10.1089\/thy.2018.0315","journal-title":"Thyroid"},{"issue":"6","key":"2358_CR15","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1530\/eje-20-1490","volume":"184","author":"CMJ van Kinschot","year":"2021","unstructured":"van Kinschot CMJ, Soekhai VR, de Bekker-Grob EW, Visser WE, Peeters RP, van Ginhoven TM, van Noord C (2021) Preferences of patients and clinicians for treatment of graves\u2019 disease: a discrete choice experiment. Eur J Endocrinol 184(6):803\u2013812. https:\/\/doi.org\/10.1530\/eje-20-1490","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2358_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000336101","volume":"1","author":"K Poppe","year":"2012","unstructured":"Poppe K, Hubalewska-Dydejczyk A, Laurberg P, Negro R, Vermiglio F, Vaidya B (2012) Management of hyperthyroidism in pregnancy: results of a survey among members of the European Thyroid Association. Eur Thyroid J 1(1):34\u201340. https:\/\/doi.org\/10.1159\/000336101","journal-title":"Eur Thyroid J"},{"issue":"1","key":"2358_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12020-022-02989-x","volume":"76","author":"J Hidalgo","year":"2022","unstructured":"Hidalgo J, Vallejo S, El Kawkgi OM, Ospina NMS, Maraka S, Brito JP (2022) Individualized graves\u2019 disease remission rates conversations: a videographic analysis of medical encounters. Endocrine 76(1):237\u2013239. https:\/\/doi.org\/10.1007\/s12020-022-02989-x","journal-title":"Endocrine"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02358-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02358-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02358-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T10:16:57Z","timestamp":1726136217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02358-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":17,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["2358"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02358-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was not subject to the Medical Research Involving Human Subjects Act (WMO) as it does not impose any act or mode of behavior on the subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Since results of the questionnaire were fully anonymous and respondents were not personally approached for participation in the questionnaire, it was not necessary to obtain informed consent from each subject.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}